Numeric Biotech expands its team with biotech industry veterans

Rotterdam, The Netherlands, June 5, 2018 – Numeric Biotech BV, a privately held biotechnology company creating therapeutics to cure and prevent age-related diseases, announces recent additions to its executive team.

Lars Bastiaanse will join Numeric as Chief Development Officer. Lars has over 25 years of experience in clinical development, project management and general management in pharmaceutical, biotech, but also CRO/Consultancy companies. He was responsible for various development phases for many biotech products. At Johnson & Johnson for instance, Lars was incremental for the development of immunology products currently on the market such as Intelence, and Edurant. Lars obtained a MSc degree in pharmacy and completed his PhD degree in Medicinal Sciences at the Leiden University Medical Centre (The Netherlands).

Joining as VP Regulatory Affairs and Quality, Joost van Bree has over 20-years industry experience in successfully bringing conventional and biotech drugs through development and regulatory approval. He has worked in various international management positions in the fields of drug development, clinical pharmacology, and regulatory affairs with Sandoz (now Novartis) in Switzerland, Teva, Immunovo and Pepscan. At Pharming he held the position of VP Clinical Development and Regulatory Affairs. In addition, he brings the experience of raising funds of over Euro 100 Million with venture capital financing as well as a successful IPO and secondary listing. Joost holds an MSc in Pharmacy and a PhD in Clinical Pharmacology, both from Leiden University (The Netherlands).

Patricia Ringeling, will join Numeric as VP Intellectual Property. Patricia has over 20 years of experience in patent practice including litigation, as a qualified Dutch and European Patent Attorney. She worked at companies such as the Dutch Patent office (NLO), DSM and Pharming but also various start-up companies in the life science industry. Patricia studied chemistry with minors immunology and oncology, at the University of Amsterdam, holds a PhD from the Erasmus University Medical Center Rotterdam (The Netherlands) and a Certificate in Intellectual Property from Queen Mary, University of London.

“We are very happy to be able to attract this talent and relevant experience that matches the level of potential of Numeric’s mission to attack the age-related diseases with our first lead oncology indication,” said Hans van Berkum, Numeric CEO.

About Numeric Biotech Numeric Biotech BV develops therapeutics to cure and prevent age-related diseases. The senolytic drugs that Numeric is creating selectively eliminates senescent cells being able to treat age-related diseases. Numeric is developing its proprietary compounds based on novel pathways e.g. FOXO4-P53. The initial focus of the development is therefor on various oncology indications and other age-related diseases such as OsteoArthritis and chronic kidney disease.

More information is available at: